

# Negative affectivity predicts decreased pain tolerance during low-grade inflammation in healthy women

Lacourt, T.e.; Houtveen, J.h.; Veldhuijzen van Zanten, Jet; Bosch, J.a.; Drayson, M.t.; Van Doornen, L.j.p.

DOI:

[10.1016/j.bbi.2014.10.003](https://doi.org/10.1016/j.bbi.2014.10.003)

License:

Other (please specify with Rights Statement)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Lacourt, TE, Houtveen, JH, Veldhuijzen van Zanten, J, Bosch, JA, Drayson, MT & Van Doornen, LJP 2015, 'Negative affectivity predicts decreased pain tolerance during low-grade inflammation in healthy women', *Brain, Behaviour, and Immunity*, vol. 44, pp. 32-36. <https://doi.org/10.1016/j.bbi.2014.10.003>

[Link to publication on Research at Birmingham portal](#)

## **Publisher Rights Statement:**

NOTICE: this is the author's version of a work that was accepted for publication in *Brain, Behavior, and Immunity*. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published as Lacourt, T.E., Houtveen, J.H., Veldhuijzen van Zanten, J.J.C.S., Bosch, J.A., Drayson, M.T., Van Doornen, L.J.P., Negative affectivity predicts decreased pain tolerance during low-grade inflammation in healthy women, *Brain, Behavior, and Immunity* (2014), doi: <http://dx.doi.org/10.1016/j.bbi.2014.10.003> DOI: 10.1016/j.bbi.2014.10.003

## **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

# Accepted Manuscript

Short Communicaton

Negative affectivity predicts decreased pain tolerance during low-grade inflammation in healthy women

T.E. Lacourt, J.H. Houtveen, J.J.C.S. Veldhuijzen van Zanten, J.A. Bosch, M.T. Drayson, L.J.P. Van Doornen


PII: S0889-1591(14)00476-0  
DOI: <http://dx.doi.org/10.1016/j.bbi.2014.10.003>  
Reference: YBRBI 2460

To appear in: *Brain, Behavior, and Immunity*

Received Date: 2 January 2014  
Revised Date: 2 October 2014  
Accepted Date: 3 October 2014

Please cite this article as: Lacourt, T.E., Houtveen, J.H., Veldhuijzen van Zanten, J.J.C.S., Bosch, J.A., Drayson, M.T., Van Doornen, L.J.P., Negative affectivity predicts decreased pain tolerance during low-grade inflammation in healthy women, *Brain, Behavior, and Immunity* (2014), doi: <http://dx.doi.org/10.1016/j.bbi.2014.10.003>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1  
2  
3  
4 **Negative affectivity predicts decreased pain tolerance during low-grade inflammation in**  
5  
6 **healthy women**  
7  
8  
9

10  
11 Lacourt, T.E.<sup>1,2\*</sup>, Houtveen, J.H.<sup>1,3</sup>, Veldhuijzen van Zanten, J.J.C.S.<sup>4</sup>, Bosch, J.A.<sup>4,5,6</sup>, Drayson,  
12  
13 M.T.<sup>7</sup>, Van Doornen, L.J.P.<sup>1</sup>  
14  
15  
16  
17  
18  
19  
20

21 **Affiliations:**  
22

23 <sup>1</sup> Department of Clinical and Health Psychology, Utrecht University, Heidelberglaan 1, 3584 CS Utrecht, The  
24  
25 Netherlands.  
26

27 <sup>2</sup> Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe  
28  
29 Boulevard, Unit 1450, Houston, Texas 77030, USA.  
30

31 <sup>3</sup> Department of Psychiatry, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.  
32

33 <sup>4</sup> School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, B15 2TT, United  
34  
35 Kingdom  
36

37 <sup>5</sup> Department of Clinical Psychology, University of Amsterdam, Weesperplein 4, 1018 XA, Amsterdam, The  
38  
39 Netherlands  
40

41 <sup>6</sup> Mannheim Institute of Public Health, Social and Preventive Medicine (MIPH), Mannheim Medical Faculty,  
42  
43 University of Heidelberg, Ludolf-Krehl-Strasse 7-11, D-68167 Mannheim, Germany  
44

45 <sup>7</sup> Division of Immunity and Infection, Medical School, University of Birmingham, Birmingham, B15 2TT, United  
46  
47 Kingdom  
48  
49  
50  
51  
52  
53

54 \*Corresponding author, present address: The University of Texas MD Anderson Cancer Center,  
55  
56 Department of Symptom Research, 1515 Holcombe Boulevard Unit 1450, Houston, Texas  
57  
58 77030, USA, tlacourt@mdanderson.org, tel. (001) 713 794 5464.  
59  
60  
61  
62  
63  
64  
65

## Abstract

**Introduction:** Experimental animal studies provided evidence for a synergistic effect of immunological and psychological stressors on subsequent sickness behaviors. Up to now, little corroborating evidence for such synergy exists for humans, in whom it may provide a mechanism leading to the expression of functional somatic symptoms. The aim of the present study was to determine an interaction between stress(-vulnerability) and an immunological activation on experimental pain sensitivity, i.e., pressure pain threshold and tolerance in healthy humans.

**Methods:** In healthy female participants ( $n=25$ , mean age 22.3 years), negative affectivity (NA) and experienced stress were assessed by questionnaire before receiving a *Salmonella typhi* vaccine or saline control in a randomized blinded cross-over design. Pressure pain threshold was assessed at the lower back and calves and pain tolerance was assessed at the thumbnail, before and six hours after each injection.

**Results:** Vaccination induced leukocytosis (+100%) and increased serum IL-6 (+670%). NA predicted decreased pain tolerance after vaccination ( $\beta=-.57$ ,  $p=.007$ ), but not after placebo ( $\beta=.25$ ,  $p=.26$ ). Post-hoc analyses also demonstrated an association with administration order.

**Discussion:** NA moderated the effects of inflammation on pain tolerance. This finding is consistent with a synergistic model whereby inflammation may lower the threshold for pain reporting in individuals with increased vulnerability for somatic symptom reporting.

**Keywords:** inflammation; inflammatory response; interleukin-6; cytokines; pain sensitivity; algometry; pain tolerance; pain threshold; pressure pain; experimental pain; vaccine; placebo; randomized control; stress; life events; negative affectivity; negative affect; human;

## 1. Introduction

In reaction to an immunological challenge, immune-to-brain communication leads to a constellation of reversible behavioral and affective changes, denoted as sickness behavior (Hart, 1988; Kent et al., 1992). These include lethargy, social withdrawal, and enhanced sensitivity to pain (Larson and Dunn, 2001; Yirmiya et al., 1994). Animal studies have demonstrated that (psychological) stress factors may sensitize this immune-to-brain communication, resulting in a prolonged or more severe expression of sickness behavior symptoms when an immunological stressor is applied (Anisman et al., 2007; Gibb et al., 2013). Sensitization for sickness behaviors may thus entail dual involvement of immunological and psychological factors.

Such synergism might be applicable to humans as a possible explanatory mechanism for the experience of somatic symptoms or syndromes that cannot be fully explained by a present medical condition (i.e., functional somatic (FS) syndromes), such as in irritable bowel syndrome, fibromyalgia, and chronic fatigue syndrome (Dantzer, 2005). An interesting feature of such a dual-factor or interactive model is that it could link two independent observations: First, that FS symptoms are associated with a history of elevated stress exposures (Anderberg et al., 2000; Heim et al., 2006) and second, that FS symptom onset appears linked with immune activation or an increased infection load (Lacourt et al., 2013; Moss-Morris and Spence, 2006).

The aim of the current study was to investigate the possible synergistic effects of psychological stress(-vulnerability) factors and immunological activation on pain sensitivity. Increased pain sensitivity (i.e., a lower threshold for describing a stimulus as painful and a reduction in the level of pain that is considered tolerable) is a prominent symptom in many FS syndromes (Bradley, 2008; Stabell et al., 2013) and a typical aspect of sickness behavior with a reasonable degree of objectivity in humans (c.f., Benson et al., 2012). We assessed perceived

1  
2  
3  
4 stress, cumulative life events, and negative affectivity (NA) as psychological vulnerability  
5 factors in healthy subjects, followed by a (placebo-controlled) *Salmonella typhi* vaccine.  
6

7  
8 Specifically, we tested the hypothesis that psychological vulnerability factors and immune  
9 activation by vaccination jointly enhance pain sensitivity. The present study was limited to  
10 women as they show a substantially higher prevalence of FS symptoms (Fink et al., 2007).  
11  
12  
13  
14  
15  
16  
17  
18

## 19 **2. Methods**

### 20 *2.1 Participants*

21  
22 The present study involved 27 healthy non-smoking female participants, recruited among  
23 students and staff of the University of Birmingham by poster advertisement and word of mouth.  
24  
25  
26  
27  
28

29 Inclusion criteria were an age between 18 and 50 years old and use of oral contraception.

30 Excluded were volunteers reporting diabetes mellitus, asthma, congestive heart failure, any  
31 psychiatric disorder, recent history of cancer, inflammatory disease, cardiovascular disease,  
32 chronic obstructive pulmonary disorder, wearing a pacemaker, and those taking any medications  
33 with known immune modulatory properties. Finally, participants were excluded if they were  
34 unwell on the day of testing or fell ill between the two test-days. Eligible persons received either  
35 a monetary incentive or credits for participation. The study protocol was approved by the Health  
36 Research Authority NRES Committee West Midlands – South Birmingham and all participants  
37 provided informed consent.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

### 53 *2.2 Study design*

54  
55 *Salmonella typhi* capsular polysaccharide vaccine (0.025 mg in 0.5 ml, Typhim Vi, Sanofi  
56 Pasteur, UK) was used as the immunological challenge. In a placebo-controlled cross-over  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 design, participants were tested in two conditions (i.e. vaccination or saline) on two test-days,  
5  
6 separated by at least seven days. The order of conditions was counterbalanced across the  
7  
8 participants and participants were blinded to the conditions.  
9

### 10 11 12 13 14 *2.3 Protocol*

15  
16 Informed consent was obtained on an initial appointment, which involved screening for inclusion  
17  
18 and exclusion criteria and administration of questionnaires (see below). To reduce variance in  
19  
20 anti-conceptive hormones within and across participants, participants with monophasic pills were  
21  
22 tested during the three weeks of pill use, and participants with either biphasic or triphasic pills  
23  
24 were tested within the first ten days after a stop week.  
25  
26

27  
28 With the exception of the injection (vaccine or saline), both test-day protocols were identical.  
29  
30 Participants reported between 8.00 and 11.00 a.m. at the Behavioral Immunology Laboratory of  
31  
32 University of Birmingham, upon which baseline measures were obtained of heart rate, blood  
33  
34 pressure, body temperature, and pain sensitivity. A blood sample was obtained approximately 15  
35  
36 minutes after arrival. Next, the participants performed several cognitive tasks (data not reported  
37  
38 here), and were subsequently injected with either vaccine or saline followed by a 30 minute rest.  
39  
40 All procedures were repeated at six hours post-injection, which coincides with a peak increase in  
41  
42 vaccine-induced IL-6 and leucocytosis (Paine et al., 2013). Participants were allowed to leave the  
43  
44 laboratory in between test-sessions.  
45  
46  
47  
48  
49

### 50 51 52 53 *2.4 Immunological measures*

54  
55 Blood samples were obtained by venipuncture and collected in vacutainers (Becton &  
56  
57 Dickenson), and EDTA plasma and serum was subsequently extracted. Analyses for white blood  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 cell (WBC) count and differential were done using a Coulter counter (Beckman Coulter, Inc.).  
5  
6 Serum was analysed for the inflammatory markers interleukin-6 (IL-6) and tumor necrosis  
7  
8 factor-alpha (TNF- $\alpha$ ) using high sensitivity ELISAs (Quantikine HS Human IL-6 ELISA and  
9  
10 Quantikine HS Human TNF- $\alpha$ , both R&D Systems, UK) in accordance with the manufacturer's  
11  
12 instructions. The reported sensitivity of the assays was 0.039 pg/ml and 0.106 pg/ml for IL-6 and  
13  
14 TNF-  $\alpha$  respectively, with recorded intra-assay and inter-assay variations both <10%.  
15  
16  
17  
18  
19  
20

### 21 *2.5 Stress sensitivity and psychological stress*

22  
23 As a measure of stress sensitivity, negative affectivity (NA) was measured with the NA subscale  
24  
25 of the Positive and Negative Affect Scale (PANAS) (Watson et al., 1988). Psychological stress  
26  
27 was measured with the Perceived Stress Questionnaire (PSQ) (Levenstein et al., 1993) and the  
28  
29 Life Events Scale for Students (LESS) (Clements and Turpin, 1996; Linden, 1984). A detailed  
30  
31 description of all scales is provided in the online supplement.  
32  
33  
34  
35  
36  
37

### 38 *2.6 Pain sensitivity*

39  
40 Pressure pain threshold and pressure pain tolerance were assessed using a digital pressure  
41  
42 algometer (FPX50; Wagner Pain Test<sup>TM</sup>, Greenwich, USA). The procedure for assessing  
43  
44 pressure pain sensitivity has been described elsewhere (Lacourt et al., 2012). Briefly, a pressure  
45  
46 was applied and gradually increased at a rate of 100 kPa/s until the participant indicated the force  
47  
48 to become unpleasant (for pain threshold) or unbearable (for pain tolerance), upon which the  
49  
50 pressure was released. Pain thresholds were assessed three times at four body points to obtain a  
51  
52 general body measure: bilaterally at the calf muscle belly and on the lower back at the paraspinal  
53  
54 muscles of L3. A mean pain threshold was calculated by averaging over the last two  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4 measurements of all body points. Pressure pain tolerance was measured on the thumbnail of the  
5  
6 non-dominant hand. Although a general body measure taken at multiple anatomical sites would  
7  
8 have been preferable for this measure too, multiple measures of pain tolerance were considered  
9  
10 too burdensome for the participants. Pain tolerance measurements were repeated (with a  
11  
12 minimum of 30 s in between measurements) until the participant indicated that the pain tolerance  
13  
14 level was reached. The highest obtained pressure was used as pain tolerance in the analyses.  
15  
16  
17

18  
19 These algometric pain sensitivity measures showed good test-retest reliability for tests  
20  
21 repeated within one session (intraclass correlation coefficient (ICC) > .80) (Lacourt et al., 2012;  
22  
23 Potter et al., 2006) and over days (ICC > .70) (Potter et al., 2006).  
24  
25  
26  
27

## 28 29 *2.7 Statistical analyses*

30  
31 The questionnaires did not have any missing data (with the exception of the LESS item “parent  
32  
33 losing job”, N=6) and normality was adequate for all scales without visual outliers. IL-6 and  
34  
35 TNF- $\alpha$  plasma concentrations were log-transformed to gain a normal distribution, after which no  
36  
37 visual outliers were detected. Pain threshold measures showed moderate skewness and were  
38  
39 square root transformed. Transformed and non-transformed pain data yielded similar results and  
40  
41 the latter were reported.  
42  
43  
44

45  
46 The effects of vaccination were analysed with 2 Condition (saline, vaccination) x 2 Time (pre-  
47  
48 injection, post-injection) repeated measures analyses of variance (ANOVAs). The effects of NA  
49  
50 and stress were analysed by separately adding these factors as covariates to the models  
51  
52 (ANCOVAs). In case of a significant three-way interaction (Condition x Time x Stress),  
53  
54 difference-scores were calculated for pain sensitivity and threshold ( $\Delta$  = post-injection scores  
55  
56 minus pre-injection scores), resulting in  $\Delta$ -saline and  $\Delta$ -vaccine change-scores. Separate  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 regression analyses were then performed with the  $\Delta$ -variables as dependent variable and the  
5  
6 psychological factor of interest as predictor. Bonferroni correction was used to account for  
7  
8 multiple testing, resulting in an alpha of .016 for the ANCOVAs and .025 for the regression  
9  
10 analyses. The manufacturer delivered vaccines from two lots, therefore, batch was included as  
11  
12 additional factor in all analyses. Data were analysed using SPSS for windows 20.1 (IBM SPSS  
13  
14 Inc, Chicago).  
15  
16  
17  
18  
19  
20

### 21 **3. Results**

#### 22 *3.1 Sample characteristics*

23  
24 Two participants were excluded from the analyses because of illness between test-days. Mean  
25  
26 age of the final sample (N = 25) was 22.28 years (SD: 3.39, range: 18 – 30). Mean BMI was  
27  
28 22.90 (SD: 2.76, range: 18.93 – 29.74), six participants were overweight with a BMI > 25. Mean  
29  
30 scores (SD, range) for NA were 19.40 (5.92, 10 – 33), for Perceived Stress 71.80 (12.93, 52 –  
31  
32 94), and for Life Events 283.56 (125.62, 73 – 495).  
33  
34  
35  
36  
37  
38  
39  
40

#### 41 *3.2 Main effects of vaccination*

42  
43 Descriptives for the pain and immune outcomes are provided in Table 1. With the alpha set at  
44  
45 .016 vaccination was found to significantly increase WBC (+100%; condition x time:  $F(1,23) =$   
46  
47 42.19,  $p < .001$ ) and IL-6 (+670%; condition x time:  $F(1,23) = 33.37$ ,  $p < .001$ ). No effect of  
48  
49 vaccination was found for TNF- $\alpha$  (condition x time:  $F(1,23) = 0.14$ ,  $p = .71$ ). Batch did not  
50  
51 show an interaction with condition x time in any of the analyses.  
52  
53  
54

55  
56 Vaccination did not exhibit an effect on pain threshold (condition x time  $F(1,23) = 0.24$ ,  $p =$   
57  
58 .63) or pain tolerance (condition x time:  $F(1,23) = 1.23$ ,  $p = .28$ ). Post-hoc analyses showed a  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 main effect for condition order, indicating an association between vaccination and pain tolerance  
5  
6 in those receiving the vaccine first (online supplement, Table S1).  
7  
8  
9

### 10 11 3.3 Vaccine-by-stress interaction effects 12

13  
14 A significant 3-way interaction was found for NA with pain tolerance as dependent variable  
15  
16 (condition x time x NA:  $F(1,22) = 9.45, p = .006$ ). Subsequent regression analyses (alpha set at  
17  
18 .025) showed that NA was related to a decrease in pain tolerance (i.e., a negative  $\Delta$ -score) in the  
19  
20 vaccine condition ( $\beta = -.57, t(22) = -2.96, p = .007$ ) but not in the saline condition ( $\beta = .25, t$   
21  
22  $(22) = 1.16, p = .26$ ) (see Figure 1). Post-hoc analyses provided some indication that this relation  
23  
24 between NA and vaccination on  $\Delta$ -pain tolerance was apparent for participants that received  
25  
26 vaccination on their first test-day ( $r_{\text{spearman}} = -.76, p = .01$ ) and not for participants that received  
27  
28 vaccination on their second test-day ( $r_{\text{spearman}} = .13, p = .64$ ). No significant interactions were  
29  
30 found for NA with pain threshold as dependent variable or for the Perceived stress and Life  
31  
32 Event measures.  
33  
34  
35  
36  
37  
38  
39  
40

## 41 4. Discussion 42

43  
44 The current study set out to test the hypothesis that inflammatory mechanisms and stress or  
45  
46 stress-vulnerability may interactively determine pain sensitivity. In support of this idea, the  
47  
48 results showed that higher levels of NA were associated with lower tolerance to pain during  
49  
50 vaccine-induced low-grade inflammation. To our knowledge, our results are the first  
51  
52 experimental evidence from human studies that NA and inflammatory factors can interact to  
53  
54 induce increased expression of pain symptoms, reflecting that NA may induce sensitivity for this  
55  
56 aspect of sickness behaviour in humans. NA is one of the psychological factors most robustly  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 linked to physical symptom reporting and an established vulnerability factor for the experience  
5  
6 of FS symptoms (Smolderen et al., 2007; Van Diest et al., 2005; Watson & Pennebaker, 1989).  
7

8  
9 While both high NA and immunological triggers are associated with the development of  
10  
11 functional somatic symptoms (e.g., De Gucht, 2002; Lacourt et al., 2013), neither of these factors  
12  
13 alone seems to have sufficient predictive value. The interaction between NA and inflammation  
14  
15 reported here is proposed as an explanation for this observation, proposing that both factors  
16  
17 might be required. The here reported interaction between NA and inflammation is proposed as an  
18  
19 explanation for this observation by implying that both factors are needed.  
20  
21  
22

23  
24 NA, but not perceived stress or life events interacted with inflammation to increase pain  
25  
26 sensitivity. NA reflects proneness to subjective distress and unpleasurable engagement (Watson  
27  
28 et al., 1988), and is highly correlated with the personality trait neuroticism (Wilson and Gullone,  
29  
30 1999). Perceived stress and life events on the other hand represent the experience of stress.  
31  
32 Possibly, it is the more general negative state as opposed to specific events or experiences that  
33  
34 primes the system for inflammatory effects on pain sensitivity.  
35  
36  
37

38  
39 The effects of systemic inflammation on pain sensitivity and the moderating effect of  
40  
41 psychological stressors have been well described in animal models (Anisman et al., 2007; Gibb  
42  
43 et al., 2013). These models identified as key mechanism the activation of glia cells by  
44  
45 inflammatory mediators, which in turn alter neuronal functioning along the pain pathway (Hains  
46  
47 et al., 2010; Watkins et al., 2007). Recently a mechanism was proposed by Frank et al. (2013) to  
48  
49 explain how stress acts on central immune regulation, based on data showing that stress-related  
50  
51 increases of glucocorticoids (which typically have an anti-inflammatory effect) can also enhance  
52  
53 inflammatory responses to stressors, probably by sensitization of glia cells (Frank et al., 2013).  
54  
55  
56  
57 Accordingly, high NA individuals might (as a result of frequent perceived stress) have primed  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 microglia cells for new challenges. These findings from experimental animal studies provide  
5  
6 material for further mechanistic studies in humans.  
7

8  
9 NA predicted vaccine-induced changes in pain tolerance but not pain threshold. Although  
10 pain threshold and pain tolerance are both considered measures of pain sensitivity, there is  
11 evidence that they represent different processes: An earlier study using the same pain assessment  
12 methodology showed that pain tolerance is only modestly correlated to pain threshold ( $r \approx .40$ ) but  
13 moderately related to subjective sensory and affective pain ratings ( $r \approx .60$ ) (Lacourt et al., 2012).  
14 Pain threshold on the other hand showed low correlations with pain ratings ( $r \approx .30$ ). Thus, pain  
15 tolerance seems to incorporate an affective aspect of pain sensitivity, while pain threshold seems  
16 to represent a more objective sensory aspect. The present data is suggestive of the idea that the  
17 interaction between NA and inflammation is related to emotional aspects of pain sensitivity. It  
18 has been proposed that sickness behaviour is a motivational state “that reorganizes perception  
19 and action” (Dantzer, 2001). In this view, the affective or emotional aspects of pain sensitivity  
20 would be expected to change during inflammation, as these aspects underlie the individual’s  
21 withdrawing behaviour that facilitate recuperation from infection. This affective aspect in pain  
22 sensitivity is also seen in FS syndrome patients, where relations between psychological distress  
23 and pain sensitivity measures are commonly reported (Bradley, 2008; Verne et al., 2001).  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

#### 48 *4.1 Limitations and recommendations*

49  
50 A number of limitations should be noted. First, state negative affect was not assessed in this  
51 study and it cannot be ruled out that the observed decrease in pain tolerance was a consequence  
52 of increases in negative mood state induced by low-grade inflammation. The possibility of such  
53 an effect of mood is tentatively suggested by the observation that the effect of NA and  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 vaccination on pain tolerance might depend on the order in which vaccination was administered  
5  
6 (i.e., receiving the vaccine first), which might reflect a result of anticipatory anxiety. An effect of  
7  
8 state-anxiety has recently been observed in an elegant study using the (more potent) endotoxin  
9  
10 paradigm (Wegner et al., 2014). Thus, the notion of an effect of state mood deserves further  
11  
12 exploration in future studies. Second, the sample used in this study was relatively small, leading  
13  
14 to low power to detect smaller effects. Replication in better powered studies is needed to  
15  
16 determine if the observed interactive effect for NA generalizes to other psychological  
17  
18 vulnerability factors. Third, only healthy female participants were included which reduces  
19  
20 generalizability of our results. Since gender differences have been reported for pain sensitivity  
21  
22 (Fillingim et al., 2009), it is possible that such differences may also exist in inflammation-  
23  
24 induced changes in pain sensitivity. Finally, two different batches of the *Salmonella typhi*  
25  
26 vaccine were used, thereby possibly enhancing between-participants variance in immunological  
27  
28 activity. However, batch was included as a factor in all analyses, and no batch effects could be  
29  
30 demonstrated.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 In summary, NA, a trait related to a negative or stressful interpretation of events and an  
42  
43 established vulnerability factor for the development of FS symptoms, was found to interact with  
44  
45 vaccine-induced low-grade inflammation on pain tolerance. These results are in line with animal  
46  
47 models on the synergistic effects of inflammation and psychological stress on subsequent  
48  
49 sickness behaviors and may open new approaches to understanding somatic symptom reporting  
50  
51 in humans.  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 5. References

Anderberg, U.M., Marteinsdottir, I., Theorell, T., von Knorring, L., 2000. The impact of life events in female patients with fibromyalgia and in female healthy controls. *European Psychiatry* 15, 295-301.

Anisman, H., Poulter, M.O., Gandhi, R., Merali, Z., Hayley, S., 2007. Interferon-alpha effects are exaggerated when administered on a psychosocial stressor backdrop: Cytokine, corticosterone and brain monoamine variations. *Journal of Neuroimmunology* 186, 45-53.

Benson, S., Kattoor, J., Wegner, A., Hammes, F., Reidick, D., Grigoleit, J.-S., Engler, H., Oberbeck, R., Schedlowski, M., Elsenbruch, S., 2012. Acute experimental endotoxemia induces visceral hypersensitivity and altered pain evaluation in healthy humans. *Pain* 153, 794-799.

Bradley, L.A., 2008. Pathophysiologic mechanisms of fibromyalgia and its related disorders. *Journal of Clinical Psychiatry* 69, 6-13.

Clements, K., Turpin, G., 1996. The life events scale for students: Validation for use with British samples. *Personality and Individual Differences* 20, 747-751.

Dantzer, R., 2001. Cytokine-induced sickness behavior: Where do we stand? *Brain, Behavior, and Immunity* 15, 7-24.

Dantzer, R., 2005. Somatization: A psychoneuroimmune perspective. *Psychoneuroendocrinology* 30, 947-952.

De Gucht, V., 2002. Neuroticism, alexithymia, negative affect and positive affect as predictors of medically unexplained symptoms in primary care. *Acta Neuropsychiatrica* 14, 181-185.

Fillingim, R.B., King, C.D., Ribeiro-Dasilva, M.C., Rahim-Williams, B., Riley, J.L., III, 2009. Sex, Gender, and Pain: A Review of Recent Clinical and Experimental Findings. *Journal of Pain* 10, 447-485.

1  
2  
3  
4 Fink, P., Toft, T., Hansen, M.S., Ørnboel, E., Olesen, F., 2007. Symptoms and syndromes of bodily  
5 distress: An exploratory study of 978 internal medical, neurological, and primary care patients.  
6  
7  
8 Psychosomatic Medicine 69, 30-39.  
9

10  
11 Frank, M., Watkins, L., Maier, S., 2013. Stress-induced glucocorticoids as a neuroendocrine alarm signal  
12 of danger. Brain, Behavior, and Immunity 33, 1-6.  
13  
14

15  
16 Gibb, J., Al-Yawer, F., Anisman, H., 2013. Synergistic and antagonistic actions of acute or chronic social  
17 stressors and an endotoxin challenge vary over time following the challenge. Brain, Behavior, and  
18  
19 Immunity 28, 149-158.  
20  
21

22  
23 Hains, L.E., Loram, L.C., Weiseler, J.L., Frank, M.G., Bloss, E.B., Sholar, P., Taylor, F.R., Harrison,  
24 J.A., Martin, T.J., Eisenach, J.C., Maier, S.F., Watkins, L.R., 2010. Pain intensity and duration can be  
25  
26 enhanced by prior challenge: Initial evidence suggestive of a role of microglial priming. Journal of Pain  
27  
28 11, 1004-1014.  
29  
30  
31

32  
33 Hart, B.L., 1988. Biological basis of the behavior of sick animals. Neuroscience and Biobehavioral  
34  
35 Reviews 12, 123-137.  
36  
37

38 Heim, C., Wagner, D., Maloney, E., Papanicolaou, D.A., Solomon, L., Jones, J.F., Unger, E.R., Reeves,  
39  
40 W.C., 2006. Early adverse experience and risk for chronic fatigue syndrome - Results from a population-  
41  
42 based study. Archives of General Psychiatry 63, 1258-1266.  
43  
44

45 Kent, S., Bluthé, R.M., Kelley, K.W., Dantzer, R., 1992. Sickness behavior as a new target for drug  
46  
47 development. Trends in Pharmacological Sciences 13, 24-28.  
48  
49

50 Kirsten, T.B., Taricano, M., Florio, J.C., Palermo-Neto, J., Bernardi, M.M., 2010. Prenatal  
51  
52 lipopolysaccharide reduces motor activity after an immune challenge in adult male offspring. Behavioural  
53  
54 Brain Research 211, 77-82.  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4 Lacourt, T.E., Houtveen, J.H., Smeets, H.M., Lipovsky, M.M., van Doornen, L.J.P., 2013. Infection load  
5 as a predisposing factor for somatoform disorders: evidence from a dutch general practice registry.  
6  
7

8 Psychosomatic Medicine 75, 759-764.  
9

10  
11 Lacourt, T.E., Houtveen, J.H., van Doornen, L.J.P., 2012. Experimental pressure-pain assessments: test-  
12 retest reliability, convergence and dimensionality. Scandinavian Journal of Pain 3, 31-37.  
13  
14

15  
16 Larson, S.J., Dunn, A.J., 2001. Behavioral effects of cytokines. Brain, Behavior, and Immunity 15, 371-  
17  
18 387.  
19

20  
21 Levenstein, S., Prantera, C., Varvo, V., Scribano, M.L., Berto, E., Luzi, C., Andreoli, A., 1993.  
22

23 Development of the Perceived Stress Questionnaire - A new tool for psychosomatic research. Journal of  
24 Psychosomatic Research 37, 19-32.  
25  
26

27  
28 Linden, W., 1984. Development and initial evaluation of a life events scale for students. Canadian  
29  
30 Counsellor 18, 106-110.  
31

32  
33 Moss-Morris, R., Spence, M., 2006. To "lump" or to "split" the functional somatic syndromes: Can  
34  
35 infectious and emotional risk factors differentiate between the onset of chronic fatigue syndrome and  
36  
37 irritable bowel syndrome? Psychosomatic Medicine 68, 463-469.  
38  
39

40  
41 Paine, N.J., Ring, C., Bosch, J.A., Drayson, M.T., van Zanten, J.J.C.S.V., 2013. The time course of the  
42  
43 inflammatory response to the Salmonella typhi vaccination. Brain Behavior and Immunity 30, 73-79.  
44  
45

46  
47 Potter, L., McCarthy, C., Oldham, J., 2006. Algometer reliability in measuring pain pressure threshold  
48  
49 over normal spinal muscles to allow quantification of anti-nociceptive treatment effects. International  
50  
51 Journal of Osteopathic Medicine 9, 113-119.  
52

53  
54 Smolderen, K.G.E., Vingerhoets, A.J.J.M., Croon, M.A., Denollet, J., 2007. Personality, psychological  
55  
56 stress, and self-reported influenza symptomatology. BMC Public Health 7, 1-6.  
57  
58  
59  
60  
61  
62  
63  
64  
65



- 1  
2  
3  
4 Stabell, N., Stubhaug, A., Flægstad, T., Nielsen, C.S., 2013. Increased pain sensitivity among adults  
5 reporting irritable bowel syndrome symptoms in a large population-based study. *Pain* 154, 385-392.  
6  
7  
8  
9 Van Diest, I., De Peuter, S., Eertmans, A., Bogaerts, K., Victoir, A., Van den Bergh, O., 2005. Negative  
10 affectivity and enhanced symptom reports: Differentiating between symptoms in men and women. *Social*  
11 *Science & Medicine* 61, 1835-1845.  
12  
13  
14  
15  
16 Verne, G.N., Robinson, M.E., Price, D.D., 2001. Hypersensitivity to visceral and cutaneous pain in the  
17 irritable bowel syndrome. *Pain* 93, 7-14.  
18  
19  
20  
21 Watkins, L.R., Hutchinson, M.R., Milligan, E.D., Maier, S.F., 2007. "Listening" and "talking" to neurons:  
22 Implications of immune activation for pain control and increasing the efficacy of opioids. *Brain Research*  
23 *Reviews* 56, 148-169.  
24  
25  
26  
27  
28 Watson, D., Clark, L.A., Tellegen, A., 1988. Development and validation of brief measures of positive  
29 and negative affect - The PANAS scales. *Journal of Personality and Social Psychology* 54, 1063-1070.  
30  
31  
32  
33 Watson, D. & Pennebaker, J.W., 1989. Health complaints, stress, and distress: Exploring the central role  
34 of negative affectivity. *Psychological Review* 96, 234-254.  
35  
36  
37  
38 Wegner, A., Elsenbruch, S., Maluck, J., Grigoleit, J.S., Engler, H., Jager, M., Spreitzer, I., Schedlowski,  
39 M., Benson, S., 2014. Inflammation-induced hyperalgesia: Effects of timing, dosage, and negative affect  
40 on somatic pain sensitivity in human experimental endotoxemia. *Brain, Behavior, and Immunity* [Epub  
41 ahead of print] doi:10.1016/j.bbi.2014.05.001.  
42  
43  
44  
45  
46  
47  
48 Wilson, K., Gullone, E., 1999. The relationship between personality and affect over the lifespan.  
49 *Personality and Individual Differences* 27, 1141-1156.  
50  
51  
52  
53 Wright, C.E., Strike, P.C., Brydon, L., Steptoe, A., 2005. Acute inflammation and negative mood:  
54 Medation by cytokine activation. *Brain, Behavior, and Immunity* 19, 345-350.  
55  
56  
57  
58 Yirmiya, R., Rosen, H., Donchin, O., Ovadia, H., 1994. Behavioral effects of lipopolysaccharide in rats -  
59 Involvement of endogenous opioids. *Brain Research* 648, 80-86.  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 Table 1. Mean (untransformed)  $\pm$ SD of the dependent variables per assessment.  
5  
6  
7

8  
9 Figure 1. Scatterplot depicting the relation between NA and change in pain tolerance (a negative  
10 score indicates a decrease in pain tolerance from pre- to post-injection) within the saline  
11 condition (left panel) and the vaccine condition (right panel).  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

	Saline		Vaccination	
	Pre-injection	Post-injection	Pre-injection	Post-injection
WBC ( $10^9/L$ )	5.82 $\pm$ 1.78	7.21 $\pm$ 1.96*	5.80 $\pm$ 1.33	10.57 $\pm$ 3.37*
Interleukin-6 (pg/ml)	1.77 $\pm$ 2.86	1.69 $\pm$ 2.34	0.84 $\pm$ 1.25	5.66 $\pm$ 3.33*
TNF- $\alpha$ (pg/ml)	2.00 $\pm$ 3.37	5.37 $\pm$ 9.35	3.89 $\pm$ 6.17	6.45 $\pm$ 9.99
Pain threshold (kPa)	391.27 $\pm$ 186.55	405.02 $\pm$ 175.53	398.15 $\pm$ 150.26	392.27 $\pm$ 148.79
Pain tolerance (kPa)	930.65 $\pm$ 189.97	907.12 $\pm$ 204.79	954.19 $\pm$ 168.39	899.27 $\pm$ 213.63

\* Significantly different from Pre-injection at  $p < .001$ .



Stress sensitivity and immune activation interacted to increase sensitivity to pain.

Trait negative affect predicted lower pain tolerance under induced mild inflammation.

This interaction suggests a mechanism that may underlie functional pain symptoms.

ACCEPTED MANUSCRIPT